GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Accounts Receivable

Oculis Holding AG (FRA:CR5) Accounts Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Oculis Holding AG's accounts receivables for the quarter that ended in Mar. 2024 was €0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Oculis Holding AG's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was €1.70.


Oculis Holding AG Accounts Receivable Historical Data

The historical data trend for Oculis Holding AG's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Accounts Receivable Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Accounts Receivable
- - - -

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oculis Holding AG Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Oculis Holding AG Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Oculis Holding AG's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Oculis Holding AG's accounts receivable are only considered to be worth 75% of book value:

Oculis Holding AG's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(82.758+0.75 * 0+0.5 * 0-20.375
-0-0)/36.7403
=1.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Oculis Holding AG Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (FRA:CR5) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines